Alzamend Neuro, Inc. Common Stock (ALZN)
Alzamend Neuro, Inc. (ALZN) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and psychiatric disorders. The company's pipeline primarily includes therapies targeting conditions such as Alzheimer's disease, with an emphasis on novel approaches to address unmet medical needs in mental health and neurological health.
Company News
Over 25 therapies from 20+ pharmaceutical companies are currently in various clinical trial stages for bipolar disorder treatment, with promising new drug candidates targeting different neurological mechanisms.
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aldeyra Therapeutics The Trade: Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million. What’s Happening: On April ...
The Securities and Exchange Commission has filed a lawsuit against eight individuals who allegedly earned $100 million via stock manipulation.
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The company hopes to advance the standard of care for people with dementia.